Thermo Fisher Scientific (TMO) Cash from Financing Activities (2009 - 2026)

Thermo Fisher Scientific has reported Cash from Financing Activities for 18 years, with the latest figure at -$1.6 billion in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at -$1.6 billion, down 58.53% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.4 billion (up 140.61% YoY), and the FY2025 annual result was $1.8 billion, up 126.52% from the prior year.
• Cash from Financing Activities slipped to -$1.6 billion in Q2 2026, from $1.1 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.5 billion in Q4 2025 and troughed at -$3.7 billion in Q4 2024.
• A 5-year average of -$661.2 million and a median of -$1.1 billion in 2024 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2022, when Cash from Financing Activities plunged 2406.58%; it then jumped 1328.48% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $2.4 billion in 2022, then tumbled by 159.72% to -$1.4 billion in 2023, then slumped by 156.72% to -$3.7 billion in 2024, then soared by 196.18% to $3.5 billion in 2025, then tumbled by 144.55% to -$1.6 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.6 billion in Q2 2026, $1.1 billion in Q1 2026, and $3.5 billion in Q4 2025.